chloroquine and cardiac toxicity

Last edited 07/2022 and last reviewed 08/2022

Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics

Hydroxychloroquine is indicated for treatment of rheumatoid arthritis, systemic lupus erythematosus, and dermatological conditions aggravated by sunlight

Chloroquine is indicated for malaria prophylaxis or treatment, with some products also having indications for treatment of amoebic hepatitis and abscess, rheumatoid arthritis, and discoid or systemic lupus erythematosus

Cardiac toxicity

  • product information for hydroxychloroquine and chloroquine contains warnings about cases of cardiomyopathy resulting in cardiac failure, in some cases with fatal outcome
    • clinical monitoring for signs and symptoms of cardiomyopathy is advised for patients taking hydroxychloroquine or long-term chloroquine
      • if signs and symptoms of cardiomyopathy occur during treatment with either hydroxychloroquine or chloroquine, then treatment should be stopped
  • both hydroxychloroquine and chloroquine can prolong the QT interval, especially in overdose or when used in combination with other medicines with the potential to induce cardiac arrhythmias
    • macrolides should be used with caution in patients with a history of QT interval prolongation or in patients receiving a medicine known to cause QT prolongation
Advice for healthcare professionals:
  • an observational study has shown that co-administration of azithromycin with hydroxychloroquine in patients with rheumatoid arthritis is associated with an increased risk of cardiovascular events (including angina or chest pain and heart failure) and cardiovascular mortality
  • carefully consider the benefits and risks before prescribing systemic azithromycin or other systemic macrolide antibiotics (erythromycin or clarithromycin) to patients being treated with hydroxychloroquine or chloroquine
  • if there is a clinical need to prescribe systemic macrolide antibiotics with hydroxychloroquine or chloroquine, use caution in patients with risk factors for cardiac events and follow advice in the product information for each medicine
  • be vigilant for psychiatric reactions associated with hydroxychloroquine or chloroquine, especially in the first month of treatment; events have been reported in patients with no prior history of psychiatric disorders
  • report suspected adverse drug reactions on a Yellow Card
Advice for healthcare professionals to give to patients and carers:
  • some antibiotics (known as macrolides) taken by mouth or given as an injection at the same time as hydroxychloroquine or chloroquine have been associated with an increased risk of side effects that affect the heart
  • seek urgent medical help if you have any signs of problems with your heart (for example, palpitations, fainting, chest pain, or unexplained breathlessness)
  • some patients have also reported mental health symptoms when they started treatment with hydroxychloroquine or chloroquine
  • speak to your doctor as soon as possible if you or your family members or caregivers notice any new or worsening mental health symptoms
  • read the patient information leaflet that comes with your medicine (hydroxychloroquine or chloroquine) and keep it handy in case you need to read it again
Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19 (2)
  • treatment of patients with COVID-19 with chloroquine or hydroxychloroquine is associated with an important risk of drug-induced QT prolongation and relatively higher incidence of torsades de pointes, ventricular tachycardia, or cardiac arrest

Reference:

Related pages:

choroquine and psychiatric complications

hydroxychloroquine and chloroquine retinopathy